Eventide Asset Management LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA

Eventide Asset Management LLC purchased a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 101,748 shares of the company’s stock, valued at approximately $10,650,000. Eventide Asset Management LLC owned approximately 0.86% of Palvella Therapeutics as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Group One Trading LLC grew its holdings in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. acquired a new stake in Palvella Therapeutics in the third quarter worth $36,000. JPMorgan Chase & Co. grew its holdings in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Palvella Therapeutics in the second quarter worth $85,000. Finally, BNP Paribas Financial Markets acquired a new stake in Palvella Therapeutics in the second quarter worth $104,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on PVLA. Mizuho raised their price target on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Truist Financial set a $210.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Chardan Capital restated a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Finally, BTIG Research raised their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Palvella Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $108.81 on Monday. Palvella Therapeutics, Inc. has a fifty-two week low of $20.20 and a fifty-two week high of $151.18. The stock has a market cap of $1.56 billion, a PE ratio of -26.09 and a beta of -0.15. The firm’s 50-day simple moving average is $119.52 and its 200 day simple moving average is $108.53.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total value of $507,592.98. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 20.50% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.